To evaluate the underlying mechanisms by which sevoflurane protects the liver against ischemia/reperfusion injury evaluate the mechanism by which sevoflurane exerts this protective effect.
Introduction
The reperfusion of tissue after a prolonged ischemia results in ischemia/reperfusion (I/R) injury, which can ultimately lead to multiple organ dysfunction in cases where a severe systemic inflammatory response occurs [1] [2] [3] . Ischemia of the liver, which can occur with hepatectomy, transplantation, trauma, or shock, deprives the organ of oxygen, leading to mitochondrial dysfunction and energy deficiency 4 . Swelling of hepatocytes and endothelial cells after reperfusion contributes to narrowing of sinusoidal blood vessels and platelet aggregation, thus occluding hepatic microcirculation. The subsequent inflammatory response produces reactive oxygen species and cytokines, causing further cell damage 5 .
The liver can be protected from I/R injury to some extent with sevoflurane administration [6] [7] [8] [9] . It is thought that sevoflurane attenuates the inflammation, as some volatile anesthetics have anti-inflammatory properties 10, 11 . However, hepatic ATP levels have also been shown to decrease following I/R injury 4, 12 . Thus, sevoflurane may also protect mitochondrial function by acting on ATP-dependent potassium channels 13, 14 . The aim of the present study was to identify the underlying mechanisms by which sevoflurane protects the liver against I/R injury.
Methods
The experimental protocol was approved by the Ethics A total of 39 rats were divided into three groups: sham (n = 13), with rats receiving a median laparotomy and liver manipulation without liver ischemia; no treatment I/R (NT) (n = 13); and sevoflurane treated I/R (Sevo) (n = 13). In sham and notreatment groups, ketamine (15 mg/kg, i.p.) was administered as needed during the I/R period. In the sevoflurane group, sevoflurane (Abbot Laboratories, Chicago, IL, United States) was administered continuously via orotracheal tube through a calibrated vaporizer at a concentration of 2% expired fraction (1 MAC).
After the 4-h reperfusion, blood samples were collected via cardiac puncture, and animals were euthanized by crosssection of the abdominal aorta. Liver tissue was collected from ischemic segments for biochemical and histologic examinations.
Pulmonary tissue was collected for vascular permeability analysis.
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels
Serum AST and ALT levels were assayed using the optimized ultraviolet method (COBRAS MIRA; Roche Diagnostics, Basel, Switzerland). Results are expressed as U/L.
Oxidation and phosphorylation of liver mitochondria
Liver mitochondria were prepared as described previously 16 . Briefly, mitochondrial oxygen consumption was 
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.
Lipid peroxidation analysis
Malondialdehyde (MDA) content was evaluated as a measure of lipid peroxidation. Ischemic liver tissues (100 mg/ mL) were homogenized in 1.15% KCl buffer and centrifuged at 14,000 × g for 20 min. The supernatant was then added to a reaction mixture consisting of 1.5 mL 0.8% thiobarbituric acid, 200 μL 8.1% (v/v) sodium dodecyl sulfate, 1.5 mL 20% acetic acid (pH 3.5), and 600 μL distilled water and heated to 90°C for 45 min. After cooling to room temperature, the samples were cleared by centrifugation (10,000 × g for 10 min), and the absorbance was measured at 532 nm using malondialdehyde bis (dimethyl acetal)
as an external standard. The content of lipid peroxides is expressed as nmol MDA per mg of protein 19 .
Histologic analysis
Ischemic liver samples were fixed in 10% buffered formalin for standard hematoxylin and eosin staining. The same pathologist performed the histologic evaluations in a blinded manner. The severity of injury was scored according to the incidence of coagulative necrosis on a scale of 0 to 9: 0 = no necrosis, 3 = mild, 6 = moderate, 9 = severe (Table 1) 20 . 
Determination of inflammatory mediators
Serum levels of tumor necrosis factor-α, interleukin-6, and interleukin-10 were determined by ELISA using commercially available kits (Invitrogen of Thermo Fisher Scientific, Waltham,
MA, United States).

Lung tissue microvascular permeability analysis
Increases in lung microvascular permeability were quantified by the Evans blue dye (EBD) extravasation technique as described previously 21 . EBD (20 mg/kg of body weight) was injected via the dorsal penile vein 15 min before euthanasia. After blood sample collection, the lungs were perfused with 30-50 mL of 0.9% NaCl at 10 mL/min using a syringe pump (model 975;
Harvard Apparatus) and weighed. One small fragment was dried at 60°C for calculation of total dry weight. To extract the dye, the lung was incubated with formamide (4 mL/mg of tissue) for 24h at room temperature, and the absorbance of the solution at 620 nm was measured on a microplate reader (ELX 808; Bio-Tek Instruments, Winooski, VT, United States). The results are expressed as µg of EBD per g of dry weight tissue to avoid undervaluation due to edema formation 22 .
Statistical analysis
The data are expressed as mean ± SD or as median 
Results
Serum AST and ALT levels
Liver I/R resulted in significant increases in serum AST and ALT levels in no-treatment and sevoflurane groups compared Liver MDA content There were no differences in ischemic liver MDA content among groups (data not shown).
Liver histology
I/R induced necrosis in liver samples, observed as a significant increase in the coagulative necrosis score in the no-treatment and sevoflurane groups compared to the sham group (p<0.05) (Figure 3) . However, sevoflurane administration significantly reduced the severity of necrosis when compared to the untreated group (p<0.05). 
Serum levels of inflammatory mediators
I/R resulted in a significant increase in serum levels of tumor necrosis factor-α, interluekin-6, and interleukin-10 in the no-treatment and sevoflurane groups compared to the sham group (p<0.05) ( Table 2 ). However, levels were not different between the sevoflurane and no-treatment groups. Lung microvascular permeability I/R significantly increased lung microvascular permeability as assessed by EBD extravasation (p<0.05) ( Figure  4) . Sevoflurane treatment completely abrogated this, with no difference between the sham and sevoflurane groups. Although previous studies have indicated that sevoflurane suppresses the production of reactive oxygen species and reduces lipid peroxidation in liver parenchyma 6, 7 , the results presented here failed to show significant differences in liver MDA content among the groups. Additionally, sevoflurane did not significantly reduce serum levels of inflammatory factors, which is consistent with previous studies 6, 7 . This suggests that the protection afforded by sevoflurane administration is independent of the release of proinflammatory cytokines from activated Kupffer cells in I/R injury 28, 29 .
Analyses of EBD extravasation revealed that sevoflurane preserves lung microvascular permeability. As no reduction in inflammatory mediators was observed, we speculate that sevoflurane has a local beneficial effect in the lungs. This 
Conclusion
The mechanism by which this occurs cannot be fully addressed by this study alone, but it probably involves preservation of mitochondrial function and protection of lung parenchyma, without a reduction of the systemic inflammatory response.
